MYCOLOGICS, INC.

Basic Information

MYCOLOGICS, INC.
12635 E. MONTVIEW BLVD
AURORA, CO, 80045

Company Profile

n/a

Additional Details

Field Value
DUNS: 190042098
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Leishmania major nucleoside hydrolase inhibitors

    Amount: $101,950.00

    DESCRIPTION (provided by applicant): Leishmania are typanosomatid protozoans that are transmitted by phlebotomine sand flies causing leishmaniasis. Leishmaniasis is a zoonosis and affects 12 million p ...

    STTR Phase I 2007 Department of Health and Human Services
  2. A novel vaccine against Leishmania

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): Leishmania are typanosomatid protozoans that are transmitted by phlebotomine sand flies causing leishmaniasis. Leishmaniasis affects 12 million people in 88 countr ...

    SBIR Phase I 2005 Department of Health and Human Services
  3. New drugs for the treatment of leishmaniasis

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): Leishmania are typanosomatid protozoans that are transmitted by phlebotomine sand flies causing leishmaniasis. Leishmaniasis is a zoonosis and affects 12 million p ...

    SBIR Phase I 2004 Department of Health and Human Services
  4. A novel recombinant vaccine against Cryptococcus.

    Amount: $99,999.00

    DESCRIPTION (provided by applicant): Cryptococcus neoformans is an encapsulated pathogenic yeast that causes pulmonary infections and meningoencephalitis in humans and other animals. During the last ...

    STTR Phase I 2004 Department of Health and Human Services
  5. The glyoxylate cycle as a new target for antifungals

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): Fungi cause a wide spectrum of disease states. The most common examples are relatively minor, localized infections of the skin and mucous membranes such as athle ...

    SBIR Phase I 2003 Department of Health and Human Services
  6. Antifungal drugs: Beta(1,6)-glucan synthesis inhibitors

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): Fungi cause a wide spectrum of disease states. The most common examples are relatively minor, localized infections of the skin and mucous membranes such as athlete ...

    SBIR Phase I 2003 Department of Health and Human Services
  7. Inhibitors of transcription of fungal glucan synthase

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): Perhaps the most striking difference between fungal cells and human cells is that fungal cells are encased in a wall that protects them from an osmotically and im ...

    SBIR Phase I 2003 Department of Health and Human Services
  8. A novel yeast vaccine against Coccidioides Immitis

    Amount: $99,997.00

    DESCRIPTION (provided by applicant): Coccidioidomycosis, also known as San Joaquin Valley Fever, is a fungal disease caused by Coccidioides immitis that is endemic in portions of Southern Arizona, cen ...

    SBIR Phase I 2003 Department of Health and Human Services
  9. A novel vaccine for Aspergillus fumigatus

    Amount: $99,997.00

    DESCRIPTION (provided by applicant): Aspergillus fumigatus is a ubiqutous spore-bearing fungus that causes multiple diseases in humans. These include allergic pulmonary asthma, aspergillomas, and inva ...

    SBIR Phase I 2003 Department of Health and Human Services
  10. A NOVEL SCREEN FOR INHIBITORS OF FUNGAL GPI-ANCHORING

    Amount: $100,000.00

    Perhaps the most striking difference between fungal cells and human cells is that fungal cells are encased in a wall that protects them from a hostile external environment. The cell wall plays a dynam ...

    SBIR Phase I 2002 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government